GlassScriptPhysician profile
Maher Ghawji
NPI 1134181910
$12,927.30
in general payments reported to CMS, 2019-2025
55 companies · $1,937 in 2025
The $1,937 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,004 · 2020: $1,619 · 2021: $2,354 · 2022: $2,608 · 2023: $1,195 · 2024: $1,210 · 2025: $1,937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,311 · Education: $30.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,310.86 |
| Education | $30.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,264.09 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,352.64 | 2019-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $1,262.16 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $1,076.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $727.93 | 2020-2025 | Jardiance |
| Abbvie INC. | $597.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $565.92 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $557.57 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $433.43 | 2021-2025 | Recorlev |
| Pfizer INC. | $415.60 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $412.72 | 2019-2022 | |
| Beta Bionics, INC. | $300.23 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $284.92 | 2019-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $246.33 | 2019-2025 | Omnipod |
| Horizon Therapeutics Plc | $237.72 | 2019-2023 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maher Ghawji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.